USPTO Examiner LIU TRACY - Art Unit 1614

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18653608TRACE ELEMENT COMPOSITIONS, METHODS OF MAKING AND USEMay 2024October 2024Allow510NoNo
18511294SYNTHETIC ENAMEL AND USES THEREOFNovember 2023March 2025Allow1630NoNo
18549555PROCESS FOR COLOURING HAIR KERATIN FIBERS, COMPRISING THE APPLICATION OF A COMPOSITION COMPRISING AT LEAST ONE (POLY)CARBODIIMIDE COMPOUND AND A COMPOSITION COMPRISING AT LEAST ONE ASSOCIATIVE POLYMER AND A PARTICULAR COMPOUNDSeptember 2023January 2026Allow2910NoNo
18357695BROAD-SPECTRUM, MINERAL, PHOTOPROTECTIVE COMPOSITIONSJuly 2023December 2025Allow2920YesNo
18325665INJECTABLE SILK FIBROIN FOAMS AND USES THEREOFMay 2023October 2025Abandon2910NoNo
18310312ANTIFUNGAL COMPOSITES AND METHODS THEREOFMay 2023September 2025Abandon2810NoNo
18304485ABSORBABLE IRON-BASED ALLOY IMPLANTED MEDICAL DEVICEApril 2023February 2026Abandon3401NoNo
18301186THERAPEUTIC COMPOSITION FOR ARRESTING, PREVENTING AND REVERSING DENTAL DISEASEApril 2023March 2026Abandon3560YesNo
18183415DISPENSING METHOD FOR PRODUCING DISSOLVABLE UNIT DOSE FILM CONSTRUCTSMarch 2023December 2024Allow2110NoNo
18025077BACILLUS SUBTILIS STRAIN AND USE THEREOFMarch 2023February 2026Abandon3610NoNo
18112852TOPICAL COMPOSITION FOR DESTROYING, in vivo, AN EXTERNAL HYPERPLASTIC TISSUE, SUCH AS, BUT NOT LIMITED TO, A VIRAL SKIN LESION, SUCH AS, BUT NOT LIMITED TO, A VIRAL WARTFebruary 2023October 2024Allow2020NoYes
18172360BIODEGRADABLE POLYMER-NANOPARTICLE BASED IMPLANTS FOR OCULAR DRUG DELIVERYFebruary 2023March 2026Abandon3711NoNo
18168336Oral Composition and MethodsFebruary 2023October 2025Allow3200NoNo
18162479TOPICAL INSTANT SMOOTHING AND COLORING COMPOSITIONS FOR THE SKINJanuary 2023July 2025Abandon2920NoNo
18155770TEMPORARY HAIR DYE COMPOSITIONJanuary 2023September 2025Abandon3220YesNo
18074838Oral Care Compositions Containing A Gel Network PhaseDecember 2022October 2024Allow2210NoNo
17987336TOOTH ANTI-STAINING COMPOSITION, KIT AND METHOD OF USING THE SAMENovember 2022April 2025Abandon2930NoNo
17924985AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUGNovember 2022March 2026Abandon4020NoNo
18053120Natural Combination Hormone Replacement Formulations and TherapiesNovember 2022August 2025Abandon3311NoNo
17972186COSMETIC COMPOSITIONS COMPRISING DRAGLINE SPIDER SILKOctober 2022September 2025Allow3520YesNo
18046101VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSOctober 2022February 2025Abandon2810NoNo
17995054RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGINGSeptember 2022September 2025Allow3610NoNo
17933483AQUEOUS EYEBROW COSMETIC AND EYEBROW COSMETIC PRODUCTSeptember 2022November 2024Allow2620YesNo
17932547ANTI-WRINKLE COSMETIC COMPOSITION, COMPOSITION SYSTEM AND METHOD FOR COSMETIC SKIN TREATMENTSeptember 2022February 2025Abandon2910NoNo
17802347ORAL HYGIENE COMPOSITIONSSeptember 2022November 2025Abandon3810NoNo
17801817MAGNETIC RESONANCE IMAGING CONTRAST AGENT, PREPARATION METHOD AND USE THEREOFAugust 2022December 2025Abandon4010NoNo
17891646PALMITOYL TETRAPEPTIDE-20 CONJUGATED NANOSILVER PARTICLE AND USE THEREOFAugust 2022December 2024Abandon2810NoNo
17864646VEGAN SEMI-SOLID COSMETIC COMPOSITIONJuly 2022March 2025Allow3240NoNo
17826494NATURAL TISSUE SCAFFOLDS AS TISSUE FILLERSMay 2022January 2025Abandon3210NoNo
17714090TOPICAL PHARMACEUTICAL COMPOSITIONS FOR TREATING SKIN CONDITIONSApril 2022November 2025Abandon4330YesNo
17712764TOPICAL COPPER ION TREATMENTS AND METHODS OF MAKING TOPICAL COPPER ION TREATMENTS FOR USE IN VARIOUS ANATOMICAL AREAS OF THE BODYApril 2022August 2024Allow2810NoNo
17689848COMPOSITIONS WITH INCREASED COLOR SHADE STABILITYMarch 2022October 2025Abandon4430NoNo
176302051,8-CINEOL COATED IMPLANTSJanuary 2022May 2025Abandon4001NoNo
17581031FUNCTIONAL FOODS COMPRISING DIAMINE OXIDASE AND USES THEREOFJanuary 2022August 2024Allow3110NoNo
17625765COSMETIC COMPOSITION INCLUDING 5-BENZYLAMINOSALICYLIC ACID DERIVATIVE, AND TOPICAL USE THEREOFJanuary 2022December 2025Abandon4730NoNo
17571179Oral Care Compositions and Methods of UseJanuary 2022August 2024Allow3110NoNo
17550558CHEMICAL MEMBRANE COMPLEX REPAIR SOLUTION AND METHOD OF USING THE SAMEDecember 2021June 2025Abandon4221NoNo
16623742COSMETIC PRODUCT USING PHOTOCHROMIC POWDER AND METHOD OF MANUFACTURING THE SAMENovember 2021May 2025Abandon6001NoNo
17516861BIODEGRADABLE FUNCTIONAL POLYCARBONATE NANOPARTICLE CARRIES FOR DELIVERING MOLECULAR CARGONovember 2021August 2024Allow3420YesNo
17515263VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSOctober 2021March 2025Abandon4110NoNo
17513013POROUS COMPOSITES WITH HIGH-ASPECT RATIO CRYSTALSOctober 2021July 2025Allow4421NoNo
17506939POLYMER COMPOSITE FOR CONTROLLED RELEASE OF AN AGENTOctober 2021December 2024Abandon3701NoNo
17440742FLEXIBLE METAL PATCH HAVING ANTIOXIDANT ACTIVITY AND BRIGHTENING EFFECT AND METHOD FOR USING SAMESeptember 2021January 2025Abandon4020NoNo
17444510ORGANIC COUNTERANION CO-ASSEMBLY STRATEGY FOR THE FORMATION OF CYCLODEXTRIN-CONTAINING HYBRID FRAMEWORKSAugust 2021July 2024Allow3530NoNo
17390946THERMAL CONTROL OF HAIR COLOR-ALTERING COMPOSITIONSJuly 2021July 2024Allow3620YesNo
17380884ANTIMICROBIAL COSMETIC PREPARATIONJuly 2021October 2024Abandon3930NoNo
17372315LONG-ACTING POLYMERIC DELIVERY SYSTEMSJuly 2021March 2025Abandon4420NoNo
17419527ORAL ARTICLES AND METHODS OF USEJune 2021April 2025Allow4560NoNo
17295796DENTAL CLEANER AND DENTAL REMOVER FOR TEMPORARY ADHESIVESMay 2021February 2026Abandon5760NoNo
17315584SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACIDMay 2021December 2024Abandon4310NoNo
17308080Oral Care Compositions Comprising Dicarboxylic AcidMay 2021January 2026Abandon5660NoNo
17308079Oral Care Compositions Comprising Dicarboxylic AcidMay 2021February 2025Abandon4540NoNo
17245525Oral Care Composition Comprising Cuttlefish Bone Powder and Uses ThereofApril 2021December 2024Abandon4310NoNo
17289181BIS(TRIETHOXYSILYL-PROPYL)AMINE COMBINED WITH POLYVALENT METAL CATIONSApril 2021July 2025Abandon5140NoNo
17238263ORODISPERSIBLE FILMS HAVING QUICK DISSOLUTION TIMES FOR THERAPEUTIC AND FOOD USEApril 2021December 2024Abandon4310NoNo
17232020FULL ARCH DENTAL TREATMENT DEVICES AND SYSTEMSApril 2021January 2025Abandon4520NoNo
17226936METHODS OF TREATMENT USING TOPICAL COPPER ION FORMULATIONSApril 2021February 2025Abandon47100YesNo
17279365PHOTONIC BARRIER FOR TOPICAL USE, COMPRISING BISMUTH OXIDE COLLOIDSMarch 2021February 2025Allow4640YesNo
17195267TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINEMarch 2021June 2024Allow4010NoNo
17165897L-SERINE COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERSFebruary 2021March 2025Allow5030NoNo
17130405COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATIONDecember 2020April 2025Abandon5221NoYes
17253395COMPOSITION WITH LONG-LASTING CONCEALING EFFECTSDecember 2020January 2025Allow4980NoNo
17120197DENTAL CARE CANNABIS DEVICE AND USE THEREOFDecember 2020March 2025Abandon5160NoNo
17056139Docetaxel palmitate liposome and preparation method thereofNovember 2020April 2024Abandon4141NoNo
17091573BIOACTIVE GLASS COMPOSITIONS AND DENTIN HYPERSENSITIVITY REMEDIATIONNovember 2020October 2024Abandon4820NoNo
17065302SODIUM BICARBONATE IN SITU CONVERSION DRIVEN TRANSDERMAL DELIVERY OF AMINE DRUGOctober 2020January 2025Abandon5120NoNo
17044657MACROMOLECULAR AND NONPARTICULATE AGROCHEMICALS TO REDUCE VAPOR DRIFTOctober 2020December 2025Abandon6061NoNo
16990739Solid Dosage FormAugust 2020September 2024Allow4920NoYes
16961080ANTI-ADHESION COMPOSITIONJuly 2020March 2025Abandon5661NoYes
16897131CHITOSAN AND POLYETHYLENE GLYCOL COPOLYMERS AND METHODS AND DEVICES FOR USING SAME FOR SEALING A VASCULAR PUNCTUREJune 2020February 2025Abandon5641NoYes
16797580METHODS OF TREATMENT USING TOPICAL COPPER ION FORMULATIONSFebruary 2020March 2025Allow60111YesYes
16694739NON-SORPTIVE OR MINIMALLY SORPTIVE DISINFECTANT WIPESNovember 2019February 2025Allow6060YesYes
16385240BONE SUBSTITUTE COMPOSITION AND RELATED METHODSApril 2019October 2024Abandon6091NoNo
16334247Polymer-Free Drug Eluting Vascular StentsMarch 2019July 2025Allow6080YesYes
16220320BONE SUBSTITUTE MATERIALDecember 2018March 2020Allow1520NoNo
16097977COATED IMPLANTS FOR LONG-TERM CONTROLLED RELEASE OF ANTIBODY THERAPEUTICSOctober 2018October 2024Allow6060YesYes
16045678CHEMICAL MEMBRANE COMPLEX REPAIR SOLUTION AND METHOD OF USING THE SAMEJuly 2018August 2025Allow6061YesYes
16062422WATER-IN-OIL EMULSION WITH MOISTURIZING EFFECT CONTAINING HYDROPHOBIC COATED PIGMENTS AND AN AQUEOUS PHASE AT HIGH CONTENTJune 2018September 2025Abandon60111NoYes
16006721VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSJune 2018March 2025Abandon6071NoYes
15975733VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODSMay 2018February 2025Abandon6090NoYes
15820393BONE IMPLANT AND SYSTEMS AND COATINGS FOR THE CONTROLLABLE RELEASE OF ANTIMICROBIAL METAL IONSNovember 2017August 2018Allow900NoNo
15530015System and method for reducing plaque on teethNovember 2016August 2018Allow2110NoNo
15283778COMPOSITION COMPRISING DIAMINE OXIDASE FOR USE IN THE TREATMENT OR PREVENTION OF FIBROMYALGIA OR CHRONIC FATIGUE SYNDROMEOctober 2016September 2024Allow6060YesYes
15270352METHODS AND SYSTEMS FOR TREATING MEDICAL DEVICES AND FLUIDSSeptember 2016January 2022Abandon6050NoYes
15105495METHOD FOR PRODUCING AN ANTIMICROBIAL COMPOSITE MATERIAL AND ANTIMICROBIAL COMPOSITE MATERIALAugust 2016October 2024Allow60131YesNo
15149341Heat Treated Precipitated SilicaMay 2016January 2018Allow2030YesNo
14914120ORAL CARE COMPOSITIONFebruary 2016August 2017Allow1820YesNo
14903803LIPOSOMAL DRUG DELIVERY SYSTEM FOR BONE CEMENTSJanuary 2016September 2017Allow2020YesNo
14658352ADSORPTION METHOD, ADSORPTION SEPARATION METHOD, AND DRUG DELIVERY CARRIERMarch 2015April 2017Allow2520YesNo
14569545BIOABSORBABLE SUBSTRATES AND SYSTEMS THAT CONTROLLABLY RELEASE ANTIMICROBIAL METAL IONSDecember 2014February 2015Allow200NoNo
14547875DISSOLVABLE DIETARY SUPPLEMENT STRIP AND METHODS FOR USING THE SAMENovember 2014July 2016Allow2020NoNo
14121414System and method for reducing plaque on teethSeptember 2014September 2016Allow2460YesNo
14379692ACACIA GUM ADHESIVE WITH CALCIUM CARBONATE FOR ORAL ADHERING DISCSAugust 2014July 2017Allow3540NoYes
14371106Polyherbal Composition for Skin CareJuly 2014October 2016Allow2840YesNo
14364692Oral Care Composition for Enhancing Delivery of Active Agents to Mucosa/Soft Oral Tissue and Tooth Surfaces in the Oral CavityJune 2014May 2016Allow2320NoNo
14249456METHOD FOR PREPARING BIOCOMPATIBLE AND BIODEGRADABLE BIOMATERIALS BASED ON COLLAGEN AND GRANULES OF HYDROXYAPATITE/BETA-TRICALCIUM PHOSPHATE FOR USE IN SURGERY, AND BIOMATERIALS THUS OBTAINEDApril 2014April 2016Allow2520NoNo
14162090MOUTHWASH COMPOSITIONJanuary 2014June 2015Allow1710NoNo
14088768THERAPEUTIC DELIVERY SYSTEMNovember 2013August 2014Allow910YesNo
14075902POLYMERIC FILM FOR AGRICULTURAL PRODUCT STORAGE, CONTAINERS MADE THEREFROM AND RELATED METHODS OF AGRICULTURAL PRODUCT STORAGENovember 2013January 2016Allow2610NoNo
13975562DENTAL PREPARATION DELIVERY SYSTEMAugust 2013June 2014Allow911YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIU, TRACY.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
8
Examiner Affirmed
4
(50.0%)
Examiner Reversed
4
(50.0%)
Reversal Percentile
69.7%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
23
Allowed After Appeal Filing
9
(39.1%)
Not Allowed After Appeal Filing
14
(60.9%)
Filing Benefit Percentile
64.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 39.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner LIU, TRACY - Prosecution Strategy Guide

Executive Summary

Examiner LIU, TRACY works in Art Unit 1614 and has examined 89 patent applications in our dataset. With an allowance rate of 65.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner LIU, TRACY's allowance rate of 65.2% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by LIU, TRACY receive 3.56 office actions before reaching final disposition. This places the examiner in the 95% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LIU, TRACY is 42 months. This places the examiner in the 17% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +40.9% benefit to allowance rate for applications examined by LIU, TRACY. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 12.6% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 65.2% of appeals filed. This is in the 45% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.